P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY

• M. Matasar,
• N. L. Bartlett,
• L. H. Sehn,
• S. J. Schuster,
• S. Assouline,
• P. Giri,
• J. Kuruvilla,
• M. Canales,
• S. Dietrich,
• K. Fay,
• M. Ku,
• L. J. Nastoupil,
• M. C. Wei,
• S. Yin,
• I. To,
• D. Turner,
• H. Huang,
• J. Min,
• E. Penuel,
• L. E. Budde

Affiliations

M. Matasar

1 Memorial Sloan Kettering Cancer Center, New York, NY

N. L. Bartlett

2 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States of America

L. H. Sehn

3 BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

S. J. Schuster

4 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States of America

S. Assouline

5 Jewish General Hospital, Montreal, QC, Canada

P. Giri

6 Royal Adelaide Hospital, Adelaide, Australia

J. Kuruvilla

7 Princess Margaret Cancer Centre, Toronto, ON, Canada

M. Canales

8 Hospital Universitario La Paz, Madrid, Spain

S. Dietrich

9 Universitat Heidelberg, Heidelberg, Germany

K. Fay

10 St Vincent’s Hospital and Royal North Shore Hospital, Sydney

M. Ku

11 St Vincent’s Hospital, University of Melbourne, Melbourne, Australia

L. J. Nastoupil

12 MD Anderson Cancer Center, Houston, TX

M. C. Wei

13 Genentech, Inc., South San Francisco, CA, United States of America

S. Yin

13 Genentech, Inc., South San Francisco, CA, United States of America

I. To

13 Genentech, Inc., South San Francisco, CA, United States of America

D. Turner

13 Genentech, Inc., South San Francisco, CA, United States of America

H. Huang

14 Hoffmann-La Roche Ltd, Mississauga, ON, Canada

J. Min

15 Roche Products Ltd, Welwyn Garden City, United Kingdom

E. Penuel

13 Genentech, Inc., South San Francisco, CA, United States of America

L. E. Budde

16 City of Hope, Duarte, CA, United States of America